Chinese Journal of Pharmaceuticals
|
2026, 57(3): 365-371
• Pharmaceutical Management & Information •
Analysis of Class 1 New Drugs Approved by NMPA from 2016 to 2024
Full
Bingbing FAN1, Xing LING1, Jie HE1, Wen GUO1, 2, Xia WU1, *
Affiliations
- 1. China State Institute of Pharmaceutical Industry, Shanghai 201203
- 2. China National Pharmaceutical Industry Information Center, Shanghai 200040
Published: 2026-03-10
doi: 10.16522/j.cnki.cjph.2026.03.016
Outline
范冰冰, 凌星, 何洁, 郭文, 武霞.
2016至2024年我国获批的1类创新药现状分析.
中国医药工业杂志,
2026
, 57
(3)
: 365
-371
.
DOI: 10.16522/j.cnki.cjph.2026.03.016
Bingbing FAN, Xing LING, Jie HE, Wen GUO, Xia WU.
Analysis of Class 1 New Drugs Approved by NMPA from 2016 to 2024[J].
Chinese Journal of Pharmaceuticals,
2026
, 57
(3)
: 365
-371
.
DOI: 10.16522/j.cnki.cjph.2026.03.016
Year 2026 volume 57 Issue 3
129
37
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2026.03.016
- Receive Date:2025-07-26
- Online Date:2026-11-05
- Published:2026-03-10